All In Biotech

Drug Trial Radar · NCT05024318

NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma

NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma: Investigating Induced Immune Context Changes

Last checked: Nov 20, 2026Latest source record: May 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

20

Planned (sponsor's estimate)

Start

Feb 8, 2022

Primary completion

Dec 2025

Study completion Dec 2025

Sponsor

Lead sponsor
Peter MacCallum Cancer Centre, AustraliaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, open label, phase II, randomised, non-comparative clinical trial, evaluating changes in tumour-responsive T-cells following neoadjuvant stereotactic ablative body radiotherapy (SABR) with or without pembrolizumab, prior to nephrectomy, in patients with localised primary clear cell renal cell carcinoma (ccRCC).

Conditions

  • Renal Cell Carcinoma, Clear Cell, Somatic

Interventions

  • PembrolizumabDrug

    Pembrolizumab 200 mg tobe administered as a 30 minute IV infusion every 21 days for 3 cycles

  • Stereotactic Ablative RadiotherapyRadiation

    42Gy delivered in 3 fractions

  • NephrectomyProcedure

    Partial or total nephrectomy performed 9-12 weeks after first dose of Pembrolizumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. mPR post-SABR with or without pembrolizumabTime frame: At nephrectomy performed 9-12 weeks after first dose of pembrolizumab
  2. CD8+ TRM in baseline biopsy and post-nephrectomy specimen, all measured as a continuous variable.Time frame: Baseline and at nephrectomy performed 9-12 weeks after first dose of pembrolizumab
  3. TCF-1 + tumour infiltrating lymphocytes (TILs) in baseline biopsy and post-nephrectomy specimen, measured as a continuous variableTime frame: Baseline and at nephrectomy performed 9-12 weeks after first dose of pembrolizumab

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.